Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 114 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Adjuvant breast radiation therapy Clear all
Recruiting Phase 2 Interventional

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

NCT06902311
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer, Ductal Carcinoma in Situ, DCIS
Interventions
Breast Radiotherapy
Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 5, 2026, 5:31 AM EDT
Recruiting Phase 3 Interventional

Two Versus One Week Breast Radiotherapy (RT)

NCT06960707
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation therapy - 1 week, Radiation therapy - 2 weeks
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 5, 2026, 5:31 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations

NCT02917421
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 99 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

NCT03958721
View directory record Official record
Conditions
Resistant Breast Cancer, Non-metastatic Invasive Breast Cancer
Interventions
Capecitabine, Radiotherapy
Drug · Radiation
Lead sponsor
A Bapsi Chakravarthy, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

NCT03188393
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Biopsy of Breast
Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
377
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 256 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

NCT00379509
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer

NCT00054301
View directory record Official record
Conditions
Breast Cancer
Interventions
adjuvant therapy, conventional surgery, intraoperative radiation therapy
Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 5, 2026, 5:31 AM EDT
Completed No phase listed Observational

Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer

NCT02366806
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer

NCT00082641
View directory record Official record
Conditions
Breast Cancer
Interventions
autologous dendritic cell-adenovirus p53 vaccine
Biological
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

NCT00003992
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
44
States / cities
Palo Alto, California • Stanford, California • Denver, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 5, 2026, 5:31 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
45
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

NCT00005970
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 5, 2026, 5:31 AM EDT
Active, not recruiting No phase listed Observational

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

NCT04854005
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast surgery
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 5, 2026, 5:31 AM EDT
Suspended Phase 2Phase 3 Interventional

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

NCT03077841
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
15
States / cities
Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

NCT04674306
View directory record Official record
Conditions
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
Interventions
α-lactalbumin vaccine, Zymosan
Biological
Lead sponsor
George T. Budd
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

NCT00074152
View directory record Official record
Conditions
Breast Cancer
Interventions
chemotherapy, radiation therapy
Drug · Radiation
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
166
States / cities
Antioch, California • Fremont, California • Hayward, California + 122 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy

NCT00053898
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, tamoxifen citrate, Radiation Therapy
Drug · Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Enrollment
3,104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
724
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 499 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 5, 2026, 5:31 AM EDT
Completed No phase listed Observational

QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser

NCT01803516
View directory record Official record
Conditions
Breast Cancer, Radiation-Induced Telangiectasias
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer

NCT01556243
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic conventional surgery, whole breast irradiation
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
40 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
350
States / cities
Hot Springs, Arkansas • Dublin, California • Emeryville, California + 216 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 5, 2026, 5:31 AM EDT
Recruiting Phase 2Phase 3 Interventional

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

NCT05288777
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
T-DM1, Capecitabine, External Beam Radiation Therapy 0, External Beam Radiation Therapy 1
Drug · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ

NCT00003857
View directory record Official record
Conditions
Breast Cancer
Interventions
tamoxifen citrate, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
26 Years to 120 Years · Female only
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
305
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 235 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 5, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue

NCT00555841
View directory record Official record
Conditions
Breast Cancer
Interventions
ALC and Placebo
Drug
Lead sponsor
Sigma-Tau Research, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2012 · Synced Oct 5, 2026, 5:31 AM EDT
Active, not recruiting Phase 2 Interventional

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

NCT02912312
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
12
States / cities
Gilbert, Arizona • San Diego, California • Greeley, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 5, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

NCT00182793
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 5, 2026, 5:31 AM EDT